Tag Archives: Therapeutics

RESI@MaRS Panel Announcement: Early Stage Therapeutic Investors

9 Mar

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09

This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.

Tags: , , , , , ,

RESI San Francisco 2017 Panel Announcement: Early Stage Therapeutics Investors

27 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

The critical early years of drug development after lead compound selection see pre-clinical studies, IND-filing, and the design and implementation of clinical trials. While navigating the regulatory needs of the FDA may seem enough of a challenge, entrepreneurs must also consider how their drug addresses the needs of investors. Capital intensity, endpoint selection, timelines to inflection points – these are just a few topics beyond the scientific data that LSN researchers have discussed the importance of with investors.

Understanding what investors are looking for in the deal and business plan structure can help entrepreneurs immensely in their approach to funding. LSN is pleased to announce the Early Stage Therapeutics Investors panel for RESI SF 2017, where five therapeutics investors will share their perspective on evaluating deals and answer audience questions.

Joining moderator Doug Fisher, Partner, InterWest Partners:

Check out these investors’ bios, and if you haven’t registered yet, do so here or get in touch with us by reaching out to the RESI team at RESI@lifesciencenation.com.

237521341025992000

resi-san-francisco-2017

Tags: , , , , , , ,

RESI Boston Panel Announcement: Early Stage Therapeutics Investors

11 Aug

By Lucy Parkinson, Director of Research, LSN

Boston is often called the center of the global biotechnology industry, and it’s therefore no surprise that investors are flocking to RESI Boston to meet with early stage drug development entrepreneurs. LSN has gathered a panel of 5 top investors in therapeutics to share their tips and insights on the assessment of novel therapeutic technologies.

These five panelists will be sharing their expertise with RESI’s audience:

The panel will cover the challenges of raising capital for early stage drug development.  It’s a high-risk, high-reward investment sector, and these five investors have a wealth of experience in searching for the strongest early stage opportunities.  Representing diverse groups, from foundations to VC to pharma, these investors will explain how you can position your company to work with them.  If you’re interested in catching this panel live, you can sign up for RESI Boston now.

RESI-Boston-2016_v2

Tags: , , , , , , , ,

RESI on MaRS Double Panel Announcement – Early Stage Therapeutic Investors and Incubators & Accelerators Share Their Perspectives

26 May

By Christine A. Wu, Research Analyst, LSN

chrsitine

Early Stage Therapeutic Investors

It is well known that early stage therapeutic companies require a significant source of funding due to the long road of development. Despite therapeutic companies’ high-risk development timeline, many investors continue to remain focused on investing in biotechnology with a steadfast belief in the potential of the space.

For RESI on MaRS (June 23rd), LSN has assembled five highly experienced investors particularly interested in biotech therapeutics. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District, the Early Stage Therapeutic Investors Panel will be moderated by Cynthia Lavoie, Partner of TVM Capital, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the trends in investment in therapeutics, the investor’s perspective when approaching a deal in a high-risk space, and the best approach to initiate dialogue with them.

This is a tremendous opportunity for biotech life science entrepreneurs to meet and develop relationships with potential investors.

Incubators & Accelerators

It’s a huge challenge to launch a healthcare startup, but an increasing number of incubators and accelerator programs are stepping up to support early stage entrepreneurs and provide services, facilities and capital to speed their paths to market.

Leaders from five of these organizations are gathering at RESI on MaRS to share their experience of working with very early stage companies, and to explore how a startup can work with an incubator or accelerator partner to get ahead on their development pathway.

The moderator, Rebecca Yu, Head of JLABS @ Toronto, will be joined by:

Register for RESI@MaRS now to meet these investors in person.

RESI-Toronto-2016

Tags: , , , , , , , , ,

RESI@TMCx Panel Announcement: Early Stage Therapeutic Investors

10 Mar

By Lucy Parkinson, Director of Research, LSN

Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The level of risk involved at this stage deters some investors, and much has been written about the pull-back of many venture capital firms from this phase of investment. At RESI, a panel of 5 investors who are highly experienced in investing in early stage therapeutic development will discuss how they pick winning scientfic teams and support their portfolio companies through the challenges of the development process.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel will feature:

This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.

By registering for RESI@TMCx, you’ll be able to listen to the early stage therapeutic panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

RESI-Houston-2016_600

Tags: , , , , , , , ,

Hot Life Science Investor Mandate 3: CVC of Large Pharma Looking for Therapeutics and Companion Diagnostics

7 May

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Tags: , , ,

Family Offices Investing in Early Stage Therapeutics: RESI Panel Announcement

20 Nov

By Tom Crosby, RESI Conference Manager, LSN

Tom 2RESI has always aimed to bring a diverse pool of investors together to meet life science entrepreneurs, and at past events, our Family Office panels have often stolen the show.  As family offices grow in importance as a source of critical development capital for life science companies, LSN is excited to announce a second panel drawn from this category of investors: Family Offices Investing in Early Stage Therapeutics.

Family offices represent individuals and families with over $100 million in total assets, and therefore invest amounts far beyond angel capital.  As investors seeking both capital preservation and a long-term impact, many family offices have been taken an interest in biotechnology, a sector where far horizons are required and an investment has the power to make a difference for thousands, even millions, of people suffering from a serious disease.  Moderated by John Nelson, Managing Director of Genrich, Inc. the panel includes the following speakers:

Amir Heshmatpour, Founder & Managing Director, AFH Holding & Advisory

Rick Jones, Director, Broadview Ventures

Melissa Krauth, Head, Life Science Investments, Claria Bioscience

Sean Stalfort, Partner, PBM Capital

What are their particular motivations for investing in therapeutic development?  How does the more flexible nature of a family office structure affect their approach to biotech opportunities?  What, in addition to capital, can these groups bring to the table for an early stage company? How does an entrepreneur find a family office that might be interested in biotech and get in touch, and what information do they look for in the initial correspondence?

bb2

 

Tags: , , ,

← Older Entries
Newer Entries →